Heavily burdened by rising multidrug-resistant tuberculosis (MDR-TB),
"MDR-TB needs more complicated diagnosis methods, longer and much more expensive treatment compared with common TB, which causes huge economic and human resource loss," said Chen Mingting, deputy director of the
Currently, the Chinese government provides free treatment for common TB but not for MDR-TB, which costs much more for treatment. To help enrich drug choices for MDR-TB, the State Food and Drug Administration has approved the new medicine Sirturo, by Xi'an Janssen Pharmaceutical Ltd.
Worldwide, about 1/3 of the total population is infected with the bacterium that causes TB [_Mycobacterium tuberculosis_], and nearly 4 percent of those newly infected are initially resistant to multiple drugs [called primary drug resistance], according to the World Health Organization. That means that resistant forms of the disease are being transmitted directly from people to people, medical experts said.
[Primary drug resistant TB results from the direct transmission of drug resistant TB from one person to another.]
Communicated by: ProMED-mail
[The WHO has reported that TB drug resistance data are available for 2/3 of all countries in the world. Cases of multidrug resistant tuberculosis (MDR-TB) (that is, tuberculosis that is caused by a strain of _Mycobacterium tuberculosis_ that is at least resistant to 2 of the most effective drugs used to treat TB, isoniazid (INH) and
rifampin) have been reported in 80 countries, in some instances in almost 30 percent of all newly diagnosed cases (that is, primary drug resistance) and some countries reporting MDR-TB in more than 65 percent of patients who have been previously treated for TB. High rates of drug resistance were reported in
The largest country that conducted a nationwide survey in the reporting period (2007-2010) was
Phone: +27 (011) 025 3297
Fax: +27 087 9411350 / 1
Postal address: SASTM, PO Box 8216, Greenstone, 1616, South Africa
Physical address: SASTM, 27 Linksfield Road Block 2 a Dunvegan Edenvale
Registered as a Nonprofit Organisation 063-296-NPO
The content and opinions are neither pre-screened nor endorsed by the SASTM. The content should neither be interpreted nor quoted as inherently accurate or authoritative.
The information provided in SASTM Newsflashes is collected from various news sources, health agencies and government agencies. Although the information is believed to be accurate, any express or implied warranty as to its suitability for any purpose is categorically disclaimed. In particular, this information should not be construed to serve as medical advice for any individual. The health information provided is general in nature, and may not be appropriate for all persons. Medical advice may vary because of individual differences in such factors as health risks, current medical conditions and treatment, allergies, pregnancy and breast feeding, etc. In addition, global health risks are constantly evolving and changing. International travelers should consult a qualified physician for medical advice prior to departure.